Article
Boehringer Ingelheim to Use Seqster Platform
Patients in all studies can consent to longitudinal data use to accelerate RWE
Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.
Read more about the partnership.
Listen to a podcast with Seqster CEO & Co-founder Ardy Arianpour.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Videos
Related Content
